Key big pharma catalysts to kick off 2022
Important breast cancer data will come in the opening months of 2022, and Glaxo and Pfizer are due pivotal RSV results.
Lilly’s lebrikizumab looks to outdo Dupixent
Lilly will soon discover whether its purchase of Dermira was wise.
Key third-quarter readouts for big pharma
Abbvie expects more Rinvoq data in ulcerative colitis while Astrazeneca takes on myasthenia gravis, and gene therapy is in play for Pfizer and Roche.
Big pharma’s key catalysts in the second quarter
As Biogen heads towards important depression data, Sanofi looks to oncology for growth.
23andme joins health tech’s Spacmania
But more traditional device makers seem uninterested in this means of stock market listing.
